Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

3.0K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
3.0K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

931
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
931
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia.

Nature medicine·2026
Same author

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.

Parasites & vectors·2025
Same author

Leishmaniasis.

Nature reviews. Disease primers·2025
Same author

Comparative <i>in vitro</i> susceptibility of clinical <i>Leishmania</i> isolates to miltefosine and oleylphosphocholine.

Frontiers in pharmacology·2025
Same author

<i>Coxiella burnetii</i> and <i>Bartonella</i> species serology of febrile patients with an established infectious or inflammatory diagnosis in Sudan, Nepal, and Cambodia.

Microbiology spectrum·2025
Same author

Risk stratification of childhood infection using host markers of immune and endothelial activation in Asia (Spot Sepsis): a multi-country, prospective, cohort study.

The Lancet. Child & adolescent health·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 30, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

16.6K

リーシュマニア

Sakib Burza1, Simon L Croft2, Marleen Boelaert3

  • 1Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium; Médecins Sans Frontières, Delhi, India.

Lancet (London, England)
|August 22, 2018
PubMed
まとめ
この要約は機械生成です。

軽視されている熱帯病であるリーシュマニアは 世界中で何百万もの患者を抱えています いくつかの地域では進展がみられつつありますが,紛争と流出が増加し,新たな制御ツールと治療法の緊急性が強調されています.

さらに関連する動画

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.6K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

8.7K

関連する実験動画

Last Updated: Apr 30, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

16.6K
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.6K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

8.7K

科学分野:

  • 熱帯医学
  • 感染症
  • 公衆衛生

背景:

  • リーシュマニア症は 貧困に起因する寄生虫性疾患で 世界的に大きな影響を及ぼしています
  • 腸内リーシュマニア症 (VL) と皮膚リーシュマニア症 (CL) と表され,毎年70万~100万人に感染しています.
  • WHOはリーシュマニア症を 優先的に無視された熱帯疾患として分類しています

研究 の 目的:

  • リーシュマニアの現状をまとめます
  • 疾病管理の課題と新たな介入の必要性を強調する

主な方法:

  • 世界的なリーシュマニア症症例データと動向のレビュー
  • 病気の伝染と制御に影響を与える要因の分析

主要な成果:

  • 報告されたVL症例は,診断,治療,媒介者の制御が改善されたため,アジアで減少しています.
  • 東アフリカでは 継続的なVL症例が報告されています
  • 紛争と移住が 世界的に CLの発生率を急増させているのです

結論:

  • いくつかの分野での進歩にもかかわらず,リーシュマニア症の制御は依然として課題です.
  • 重要な証拠のギャップと新しいツールの必要性は,最終的な制御に不可欠です.
  • 緊急に新しい治療法と制御戦略が必要である.